Kriya to Present 10 Abstracts at the 2023 American Society of Gene and Cell Therapy Annual Meeting

May 02, 2023 04:30 PM Eastern Daylight Time PALO ALTO, Calif. & RESEARCH TRIANGLE PARK, N.C. – (BUSINESS WIRE)–Kriya Ther­a­peu­tics, Inc., a bio­phar­ma­ceu­ti­cal company developing gene therapies for conditions affecting millions of people around the world, today announced that it will present 10 abstracts at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place in Los Angeles, CA, May 16 – 20, 2023. Our team has made significant progress in areas critical to the development, man­u­fac­tur­ing, and char­ac­ter­i­za­tion of gene therapies, and we look forward to presenting at this year’s ASGCT. Kriya’s abstracts include two oral pre­sen­ta­tions and eight posters on its core technology and man­u­fac­tur­ing platforms as well as its diverse pipeline of gene therapies for oph­thal­mol­o­gy, neurology, and metabolic diseases. “We are excited to share updates as we continue to advance our diverse pipeline of gene therapies,” said Shankar Ramaswamy, M.D., Co-Founder and CEO of Kriya. ​“Our team has made significant progress in areas critical to the development, man­u­fac­tur­ing, and char­ac­ter­i­za­tion of gene therapies, and we look forward to presenting at this year’s ASGCT.” The pre­sen­ta­tions include: Oral Pre­sen­ta­tions: Title: Analysis of Mechanisms Driving Improved Adeno-Associated Vector Production by the Addition of Small Molecules Presenter: Nicholas Dietrich, Ph.D. Session Date/​Time: May 17 at 4:00 p.m. PT Location: Concourse Hall 152 & 153 Abstract number: 47 Title: A Rapid, Serotype Specific Approach to AAV Formulation Development Presenter: Robert Damitz, Ph.D. Session Date/​Time: May 18 at 2:00 p.m. PT Location: Concourse Hall 150 & 151 Abstract number: 111 Poster Pre­sen­ta­tions: Title: Sensitivity of AAV to Chemical and Physical Changes from Different Degradation Pathways Presenter: Robert Damitz, Ph.D. Session Date/​Time: May 17 at 12:00 p.m. PT Abstract number: 401 Title: Tran­scrip­tom­ic Profiling of Glycogen Storage Disease Type IX G2 Mouse Liver and Matched Plasma to Identify Biomarkers for Gene Therapy Presenter: Sasha Makohon-Moore, Ph.D. Session Date/​Time: May 17 at 12:00 p.m. PT Abstract number: 640 Title: Durability of AAV-Mediated Phenotypic Correction of Very Long-Chain Acyl-Coa Dehy­dro­ge­nase (VLCAD) Deficiency in Mice Presenter: Pilar Prentiss, M.S. Session Date/​Time: May 18 at 12:00 p.m. PT Abstract number: 1156 Title: Optimizing Viral Genome Titer Methods: A Case Study on Improving Titer Accuracy Using ITR Presenter: Rosalie Bateson Session Date/​Time: May 18 at 12:00 p.m. PT Abstract number: 1232 Title: AAV Mediated Expression of a Chimeric Ion Channel in Combination with its Ligand Varenicline Demon­strates a Dose Response Improvement in Pain Hyper­sen­si­tiv­i­ty in a Rat Model of Trigeminal Pain Presenter: Rosemarie Roeloffs, Ph.D. Session Date/​Time: May 19 at 12:00 p.m. PT Abstract number: 1292 Title: Automated Monitoring, Analytics, and Machine-Learning for Improved Large Scale AAV Vector Production Presenter: Mark Miller, Ph.D. Session Date/​Time: May 19 at 12:00 p.m. PT Abstract number: 1302 Title: A Cell-Based Potency Method to Assess the Impact of Forced Degradation Methods on AAV Drug Product Presenter: Lakmini Wasala, Ph.D. Session Date/​Time: May 19 at 12:00 p.m. PT Abstract number: 1361 Title: Development of Adeno-Associated Virus Producer Cell Lines by Small Molecule Inducible Expression of Packaging Genes Presenter: Nicholas Dietrich, Ph.D. Session Date/​Time: May 19 at 12:00 p.m. PT Abstract number: 1580 About Kriya Therapeutics Kriya Ther­a­peu­tics, Inc. is a bio­phar­ma­ceu­ti­cal company developing gene therapies for diseases affecting millions of people around the world. With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $450 million to advance a broad pipeline of gene therapies for oph­thal­mol­o­gy, neurology, and metabolic diseases. For more information, please visit www​.kriyatx​.com and follow on LinkedIn and Twitter. Contacts Ryan Flinn, VP, Head of Com­mu­ni­ca­tions Kriya Ther­a­peu­tics, Inc. Rflinn@​kriyatx.​com 510−207−7616 Research Triangle Park 1219 Shiloh Glenn Drive Durham, NC 27703 1 833 Kriya TX 1 833 574 9289 info@​kriyatx.​com LinkedIn X / Twitter

The release as fetched from its publisher. kriyatx.com ↗